Novartis reduces PDI sales contract
Executive Summary
Novartis reduces its contract with PDI for next year to 300 reps, down from 518 in 2003. The contract sales organization will support the sale of the antihypertensives Diovan and Lotrel but will no longer sell Lotensin, which will go off patent in February. Novartis upped its support of its hypertension drugs with the launch of a blood pressure awareness campaign in August (1"The Pink Sheet" Aug. 18, 2003, In Brief)...